PMH15 COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
Nov 1, 2003, 00:00
10.1016/S1098-3015(10)61772-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)61772-X/fulltext
Title :
PMH15 COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)61772-X&doi=10.1016/S1098-3015(10)61772-X
First page :
Section Title :
Open access? :
No
Section Order :
217